The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The Economic Impact of Exacerbations of Chronic Obstructive Pulmonary Disease and Exacerbation Definition: A Review
Open accessAbstract
Chronic obstructive pulmonary disease (COPD) poses a significant economic burden on society, and a substantial portion is related to exacerbations of COPD. A literature review of the direct and indirect costs of COPD exacerbations was performed. A systematic search of the MEDLINE database from 1998-2008 was conducted and supplemented with searches of conference abstracts and article bibliographies. Articles that contained cost data related to COPD exacerbations were selected for in-depth review. Eleven studies examining healthcare costs associated with COPD exacerbations were identified. The estimated costs of exacerbations vary widely across studies: $88 to $7,757 per exacerbation (2007 US dollars). The largest component of the total costs of COPD exacerbations was typically hospitalization. Costs were highly correlated with exacerbation severity. Indirect costs have rarely been measured. The wide variability in the cost estimates reflected cross-study differences in geographic locations, treatment patterns, and patient populations. Important methodological differences also existed across studies. Researchers have used different definitions of exacerbation (e.g., symptom- versus event-based definitions), different tools to identify and measure exacerbations, and different classification systems to define exacerbation severity. Unreported exacerbations are common and may influence the long-term costs of exacerbations. Measurement of indirect costs will provide a more comprehensive picture of the burden of exacerbations. Evaluation of pharmacoeconomic analyses would be aided by the use of more consistent and comprehensive approaches to defining and measuring COPD exacerbations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rabe, K. F., Hurd, S., Anzueto, A., Barnes, P. J., Buist, S. A., Calverley, P., Fukuchi, Y., Jenkins, C., Rodriguez-Roisin, R., van Weel, C., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-456so · Cited by 4,925
Cited by
Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD
Wedzicha, J. A., Banerji, D., Chapman, K. R., Vestbo, J., Roche, N., Ayers, R. T., Thach, C., Fogel, R., Patalano, F., & Vogelmeier, C. F. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516385 · Cited by 844
Chen, W., Thomas, J., Sadatsafavi, M., & FitzGerald, J. M. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00241-6 · Cited by 718
Self management for patients with chronic obstructive pulmonary disease
Zwerink, M., Brusse-Keizer, M., van der Valk, P. D., Zielhuis, G. A., Monninkhof, E. M., van der Palen, J., Frith, P. A., & Effing, T. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002990.pub3 · Cited by 572
The clinical and economic burden of chronic obstructive pulmonary disease in the USA
Ray, S., Guarascio, Finch, & Self, T. (2013) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s34321 · Cited by 425
Ritchie, A. I., & Wedzicha, J. A. (2020) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2020.06.007 · Cited by 402
Metadata
- Authors
- Toy, E. L., Gallagher, K. F., Stanley, E. L., Swensen, A. R., & Duh, M. S.
- Venue
- COPD: Journal of Chronic Obstructive Pulmonary Disease
- Publisher
- Informa UK Limited
- Published
- 2010-05
- Volume
- 7
- Issue
- 3
- Pages
- 214-228
- ISSN
- 1541-2555 (ISSN-L)
- 1541-2563
- OpenAlex
- W2021331487
- Cited by
- 247
- References
- 1
- FWCI
- 7.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Economic Impact of Exacerbations of Chronic Obstructive Pulmonary Disease and Exacerbation Definition: A Review. https://app.cochat.ai/papers/10.3109/15412555.2010.481697
- The paper
- Toy, E. L., Gallagher, K. F., Stanley, E. L., Swensen, A. R., & Duh, M. S. (2010). The Economic Impact of Exacerbations of Chronic Obstructive Pulmonary Disease and Exacerbation Definition: A Review. COPD: Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.3109/15412555.2010.481697
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.